NOPAIN ReimbursementThe NOPAIN reimbursement change, which removes Exparel from the surgical bundle and offers additional reimbursement incentives, could impact pricing strategy positively.
Patent SettlementPacira announced a settlement on Exparel patent litigation, which is viewed as a positive for the stock.
Share RepurchaseA new $300MM share repurchase program has been announced.